Anumana and Novartis partner for AI-based heart disease detection

Related Articles
Could AI and an Apple Watch ECG improve the prognosis for heart failure?
Med City News: Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the…May 11, 2022
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Biospace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial…July 12, 2022
Anumana wins FDA breakthrough status for AI algorithm to detect PH
NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced…May 24, 2022
How AI Is Shaping the Futureof Diagnostic Accuracy inReal-World Care
AI is transforming diagnostics by identifying subtle patterns, streamlining workflows, and accelerating time to diagnosis. This piece will explore how AI supports earlier and more accurate decision-making, the importance of…October 01, 2025


